Slides
Page 1
Financial Results for the First Quarter of Fiscal Year Ending March 31 , 2027 ( FY2026 ) PHC GROUP PHC Holdings Corporation August 6 , 2026 Tokyo Stock Exchange Prime Market | 6523
Page 2
2 ©PHC Holdings Corporation 2026 Disclaimer This document was prepared by PHC Holdings Corporation (referred to as the “Company,” herein) solely for informational purposes. This document does not constitute an offer to sell or a solicitation of an offer to buy any securities of the Company in the United States, Japan, or any other jurisdiction. None of the Company’s securities have been or will be registered under the United States Securities Act of 1933, as amended, and no such securities may be offered or sold in the United States absent registration oran applicable exemption from registration requirements. This document contains forward-looking statements, that reflect the Company's assumptions, outlook, and estimates based on information available to the Company as well as its plans and expectations, as of the date of this document or other date indicated. Please note that significant differences may arise between the forecasts and other forward-looking statements contained herein and the actual results, due to various factors. Readers are therefore cautioned against placing undue reliance on such forward-looking statements. Additionally, this document includes information that has not been audited or reviewed by an independent certified public accountant or audit corporation. It also contains financial information based on past financial statements or accounting documents, as well as management figures thatare not based on financial statements or accounting documents. Except as required by applicable laws or stock exchange rules and regulations, the Company assumes no obligation to update or revise any information in this document based on any subsequent developments. This document includes information derived from or based on third-party sources, including information about the markets in which the Company operate. Such information is based on statistics and other data from third-party sources as cited herein. The Company has not independently verified and cannot warrant the accuracy or completeness of any information derived from or based on third-party sources. This document is an English translation of the original Japanese language document and has been prepared solely for reference purposes. The Company makes no warranties or assurances regarding the accuracy or completeness of this English translation. In the event of any discrepancy between this English translation and the original Japanese language document, the Japanese document shall prevail in all respects. The information contained in this document is subjectto change without notice. Furthermore, any information about products (including those currently in development) contained in this document is not intended to constitute advertising or medical advice.
Page 3
3 ©PHC Holdings Corporation 2026 Contents Executive Summary FY26Q1 Financial Results Summary FY26 Full Year Forecasts Appendix 01 02 03 04 • At the beginning of FY26, some business units were subject to name clarification and reorganization. Please refer to page 27 for details. • For the meanings of business-related and financial terms and abbreviations, please refer to page 28.
Page 4
01 Executive Summary
Page 5
5 ©PHC Holdings Corporation 2026 Revenue grew significantly YoY, including FX effects. Operating profit also increased substantially due to solid BGM performance and improved profitability resulting from the CGM business transfer. Profit attributable to owners of parent increased by JPY 8.7 billion YoY. FY26Q1 Financial Highlights (JPY in 100 millions) FY26 Full Year Forecasts FY26 Q1 Financial Results Summary 3,597 Revenue 270 Operating Profit 154 Profit Attributable to Owners of Parent 907 Revenue 104 Operating Profit 63 Profit Attributable to Owners of Parent Both revenue and profit significantly exceeded the internal forecast in Q1. However, the full-year forecast remains unchanged as market trends and the business environment continue to be reviewed further, at least for 1H. +8.1％(+68)YoY Growth +171.0％(+66)YoY Growth -％(+87)YoY Growth -1.3％(-47)YoY Growth +19.0％(+43)YoY Growth -％(+149)YoY Growth Dividend Per Share JPY 42 (Interim: JPY 21, Year-end: JPY 21) (JPY in 100 millions)
Page 6
6 ©PHC Holdings Corporation 2026 Progress of Initiatives in the Value Creation Plan Enhancement of Profit Base Focus on Diagnostics & Life Sciences Supports medical reimbursement revision in June 2026. Advances technical verification and operational readiness for full-scale adoption of the Electronic Medical Record Information Sharing Service. Surpassed 25,000 Installations of E-prescription Software (as of May 2026) URL (Japanese) https://www.wemex.com/news/20260616_182.html Selected as the 2026 “Best New Diagnostic Technology Solution” by MedTech Breakthrough Awards URL https://www.epredia.com/ja/news/epredia-e1000-dx-digital-pathology-solution-named-best- new-diagnostic-technology-solution-in-2026-medtech-breakthrough-awards-program E1000 Dx was recognized for its high throughput, high-resolution, automated quality control, and system interoperability. URL (Japanese) Opened a New Infectious Disease Research Facility with BSL-3 Compliance in April Under “Drug Discovery Cluster Campus Development Project” https://www.mediford.com/assets_pdf_public/news/20260417_01.pdf Provides regulatory-compliant support for vaccine and anti-infective drug development, which accelerate drug discovery by academia and startups in Japan. Launched Ascensia CONTOUR® Comfort Pen Needles to Expand CONTOUR® Portfolio URL https://www.ascensia.com/press/press-releases/press- release/?id=3354d271-f658-4d59-8db2-f9d37c288fe9 Enhanced comfort and ease of insulin injection through a five-bevel tip and ergonomic design. Following the first three European markets, to be rolled out to several additional countries over the next two years. URL (Japanese) Expanded into clinical use in Japan following Europe and the U.S. Creates high- speed and high-resolution scans of up to 1,000 slides with automated quality control, enabling lab users to reduce workload and enhance efficiency in diagnosis. Received Class II approval for E1000 Dx Digital Pathology Solution and Launched Pathology Diagnosis Support in Japan https://www.phchd.com/jp/phc/news/2026/0324 Launched SlideMate Thermal Slide Printer URL https://www.epredia.com/news/epredia-launches-slidemate-thermal-transfer-slide-printer Enhances traceability of tissue samples through clear and durable printing. Improves pathology workflow efficiency with a compact design and integration with laboratory information systems. URL (Japanese) Expanded CO₂ Incubator Lineup https://www.phchd.com/jp/phc/news/2026/0424 Added six new models, with enhanced usability, contamination control, IoT- based equipment management, and a compact model with proprietary humidity control to support stable cell culture and improve reproducibility.
Page 7
FY26Q1 Financial Results Summary 02
Page 8
8 ©PHC Holdings Corporation 2026 FY26Q1 Results FY25 Q1 Results FY26 Q1 Results YoY Variance YoY Variance (%) Revenue 839 907 +68 +8.1% Operating Profit 38 104 +66 +171.0% Profit Before Tax -20 81 +101 - Profit Attributable to Owners of Parent -23 63 +87 - EUR/USD Against JPY 164 / 144 185 / 159 +21 / +15 - EBITDA 105 171 +66 +62.5% Adjusted EBITDA 109 173 +63 +58.1% (JPY in 100 millions)
Page 9
9 ©PHC Holdings Corporation 2026 839 895 959 952 907 FY25 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY26 Q1 38 65 67 56 104 FY25 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY26 Q1 Quarterly Trends in Revenue and Operating Profit Revenue growth in this period was driven by solid BGM performance and favorable FX. Operating profit rose 171% YoY, reflecting significant margin improvement due to revenue growth, a favorable sales mix from solid BGM sales in developed countries, the CGM business transfer, and cost reduction efforts. Operating ProfitRevenue (JPY in 100 millions) (JPY in 100 millions) +8.1% +171.0 %
Page 10
10 ©PHC Holdings Corporation 2026 31% 34% 35% 0% Revenue by Segment and Business Unit (JPY in 100 millions) FY25 Q1 FY26 Q1 Variance Results Results Excluding FX Impact Results Excluding FX Impact Diabetes Management 231 278 247 +20.2% +6.7% Healthcare Solutions 305 310 310 +1.6% +1.6% Clinical Testing 168 173 173 +2.4% +2.4% Healthcare IT Solutions 122 116 116 -5.0% -5.0% CRO 15 22 22 +47.4% +47.4% Diagnostics & Life Sciences 302 318 292 +5.4% -3.1% Pathology 136 143 128 +5.1% -5.5% Life Sciences 166 175 164 +5.6% -1.2% Consolidated 839 907 850 +8.1% +1.3% (JPY in 100 millions) Revenue 907 Revenue Composition Diabetes Management Healthcare Solutions Diagnostics & Life Sciences Others *Starting in FY26, the Biomedical and IVD Businesses were integrated into a single business called the “Life Sciences Business”. In addition, the B2B business in Indonesia, previously included in “HQ & Others”, was incorporated into the “Life Sciences Business”. Please refer to page 27 for details. Figures for FY25 are restated.
Page 11
11 ©PHC Holdings Corporation 2026 38 +46 +2 +8 +2 97 +7 104 839 +16 +4 -6 +7 -7 -2 +0 850 +57 907 Analysis of Revenue Growth and Operating Profit Growth Operating Profit Revenue (JPY in 100 millions) (JPY in 100 millions) FY25 Q1 FY26Q1 Excluding FX Impact Diabetes Management Healthcare Solutions Diagnostics & Life Sciences HQ & Others FY26 Q1 FX Impact FY25 Q1 Diabetes Management Clinical Testing Healthcare IT Solutions CRO Pathology Life Sciences HQ & Others FY26 Q1 FX ImpactFY26Q1 Excluding FX Impact Revenue Growth Rate +1.3% Operating Profit Growth Rate +151.9% *Starting in FY26, the Biomedical and IVD Businesses were integrated into a single business called the “Life Sciences Business”. In addition, the B2B business in Indonesia, previously included in “HQ & Others”, was incorporated into the “Life Sciences Business”. Please refer to page 27 for details. Figures for FY25 are restated.
Page 12
12 ©PHC Holdings Corporation 2026 231 278 247 FY25 Q1 FY26 Q1 FY26Q1 Excluding FX Impact [Diabetes Management Segment] Revenue and Operating Profit Despite the revenue decrease by the CGM business transfer, revenue increased substantially due to solid sales in Europe and the U.S where ongoing market decline, growth in emerging markets, and favorable FX effects. Operating profit also increased significantly due to strong sales with higher margin in developed markets, increased revenue in emerging markets, favorable FX, cost reduction, and the CGM business transfer. Operating ProfitRevenue － Impact of CGM transfer － Market shifts to low-price channel + Higher sales volumes in the U.S. FY25 Q1 FY26 Q1 FY26Q1 Excluding FX Impact 52 104 96 • Margin: 33.0% Growth in emerging markets+ (JPY in 100 millions) (JPY in 100 millions) ［Reference］Adjusted EBITDA + Strong performance in profitable developed countries Revenue growth in emerging markets + Reduced losses due to CGM business transfer + + Favorable FX Effect of cost reductions+ 40 92 85 FY25 Q1 FY26 Q1 FY26Q1 Excluding FX Impact Strong sales in Europe+ +20.2 % Favorable FX+ +132.2 % Market contraction in developed countries －
Page 13
13 ©PHC Holdings Corporation 2026 +1.6% 15 22 22 122 116 116 168 173 173 FY25 Q1 FY26 Q1 FY26Q1 Excluding FX Impact 305 310 310 [Healthcare Solutions Segment] Revenue and Operating Profit Revenue increased by higher volumes of general testing and growth in genetic testing in Clinical Testing business, as well as increased orders in CRO business. These factors offset the impact of lower sales of EMR/medical-receipt systems following strong replacement demand in the prior-year. Operating profit increased mainly due to higher sales of high-margin e-prescription products and improved profitability with price revision. Increased demand for e-prescription products + Decline following the surge in replacement demand for EMR/medical-receipt systems － Increased volume of general testing+ Completion of large-scale testing FY25 Q1 FY26 Q1 FY26Q1 Excluding FX Impact 35 37 37 ［Reference］Adjusted EBITDA • Margin: 3.5% Increased back orders at the beginning Increased high-margin e-prescription product sales + Restructuring costs－ Price revision+ 9 11 11 FY25 Q1 FY26 Q1 FY26Q1 Excluding FX Impact +27.6 % Operating ProfitRevenue (JPY in 100 millions) (JPY in 100 millions) Healthcare IT Solutions Clinical Testing CRO Increased sales of genetic testing+ Pricing optimization+ + +
Page 14
14 ©PHC Holdings Corporation 2026 166 175 164 136 143 128 FY25 Q1 FY26 Q1 FY26Q1 Excluding FX Impact 302 318 292 +5.4% [Diagnostics & Life Sciences Segment] Revenue and Operating Profit Revenue increased, with price revisions, consumables sales in the Pathology business, strong performance in Asia in the Life Sciences business, and favorable FX, offsetting lower equipment sales in the Pathology business. Operating profit increased due to price revisions, cost reductions, and U.S. tariff refunds. Life Sciences Pathology FY25 Q1 FY26 Q1 FY26Q1 Excluding FX Impact 37 47 43 ［Reference］Adjusted EBITDA *Starting in FY26, the Biomedical and IVD Businesses were integrated into a single business called the “Life Sciences Business”. In addition, the B2B business in Indonesia, previously included in “HQ & Others”, was incorporated into the “Life Sciences Business”. Please refer to page 27 for details. Figures for FY25 are restated. For a revenue breakdown under the previous classification, please refer to page 23. • Margin: 5.7% 9 18 17 FY25 Q1 FY26 Q1 FY26Q1 Excluding FX Impact + Effect of pricing revision + Effect of cost reductions + U.S. tariff refunds Operating ProfitRevenue (JPY in 100 millions) (JPY in 100 millions) Solid consumables sales+ Decreased equipment demand－ Effect of pricing revision+ + Favorable FX +108.2 % Life Sciences products and others IVD Strong performance in Japan/Asia+ Demand slowdown in Europe－ Lower sales in Americas－ + Strong performance in Europe/Asia+ Favorable FX
Page 15
15 ©PHC Holdings Corporation 2026 Revenue by Region In Japan, revenue increased due to favorable performance in HS. In Europe, revenue increased due to solid DM performance and favorable FX. In North America, revenue increased due to higher DM sales volumes in the U.S. and favorable FX. In Others, growth in emerging markets in DM and solid performance in Asia in D&LS contributed to higher revenue. Revenue CompositionFY25 Q1 Results FY26 Q1 Results Variance Variance (%) Japan 357 359 +2 +0.7% Europe 209 247 +38 +18.1% North America 179 189 +10 +5.6% Others 93 111 +18 +19.2% Total 839 907 +68 +8.1% (JPY in 100 millions) (JPY in 100 millions) Japan 40% Europe 27% North America 21% Others 12% Revenue 907
Page 16
16 ©PHC Holdings Corporation 2026 FY25Q1 Results FY26Q1 Results DM HS D&LS HQ & Others Consolidated DM HS D&LS HQ & Others Consolidated Operating Profit 3,953 860 871 -1,842 3,843 9,180 1,097 1,813 -1,678 10,413 + Depreciation 1,090 2,632 2,786 152 6,661 1,144 2,481 2,875 191 6,691 + Impairment loss (excluding marketable securities) - - 1 - 1 -28 - - - -28 EBITDA 5,043 3,492 3,659 -1,689 10,506 10,295 3,578 4,688 -1,486 17,075 + Transformational M&A pre-acquisition and integration costs - 36 - - 36 61 - - - 61 + Restructuring 116 - 0 250 368 -2 117 23 -0 137 + Disposal / sale of asset - - - - - - - - - - + Termination/cancellation of contracts - - - - - - - -20 - -20 + Other one-time income / expense - - - - - - - - - - Adjusted EBITDA 5,160 3,529 3,660 -1,438 10,911 10,353 3,696 4,691 -1,486 17,253 (JPY in millions) Reconciliation for Adjusted EBITDA *Starting in FY26, the B2B business in Indonesia, previously included in “HQ & Others”, was incorporated into “Diagnostics & Life Sciences” (D&LS). Please refer to page 27 for details. Figures for FY25 are restated.
Page 17
17 ©PHC Holdings Corporation 2026 Key Consolidated Balance Sheet Information Goodwill increased by JPY 1.9 billion due to FX. ROE improved to 6.0% due to higher profit attributable to owners of parent. Net debt leverage ratio decreased to 3.2x due to adjusted EBITDA growth and lower net debt. FY25 End of March FY26 End of June Variance Cash and cash equivalents 398 413 +15 Total current assets 1,762 1,752 -10 Property, plant and equipment 492 486 -6 Goodwill 2,215 2,234 +19 Intangible assets 744 725 -19 Total noncurrent assets 3,663 3,679 +15 Total Assets 5,425 5,431 +6 Borrowings (current portion) 783 783 +0 Total current liabilities 1,896 1,875 -22 Borrowings (noncurrent portion) 1,563 1,510 -53 Total noncurrent liabilities 1,920 1,871 -49 Total liabilities 3,816 3,746 -70 Equity attributable to owners of parent 1,617 1,693 +76 Non-controlling interests -8 -8 -1 Total Liabilities and Net Assets 5,425 5,431 +6 Gross debt 2,346 2,293 -53 Gross Debt / Adjusted EBITDA*1 4.5x 3.9x - Net debt*2 1,947 1,880 -68 Net Debt / Adjusted EBITDA*1 3.7x 3.2x - ROE on Profit Attributable to Owners of Parent*1,3 0.3% 6.0% - (JPY in 100 millions) *1 Adjusted EBITDA and ROE are on last 12 months basis. *2 Calculated as: current and non-current borrowings - cash and cash equivalents. *3 Calculated as: profit attributable to owners of parent divided by average equity attributable to owners of parent during the period. These are not measures in accordance with IFRS Accounting Standards.
Page 18
18 ©PHC Holdings Corporation 2026 398 +81 +67 +18 -18 -14 -11 -27 -6 -60 -16 -25 +0 +5 413 FY26Q1 Consolidated Cash Flow CF improvement continues steadily. Operating CF totaled JPY +14.3 billion, driven by solid business performance. Investing CF was JPY -3.3 billion. Financing CF was JPY -10.0 billion due mainly to debt repayments of JPY 6.0 billion and dividend payments of JPY 2.5 billion. Cash and cash equivalents increased by JPY 1.5 billion. FY25-end cash and cash equivalents FY26Q1 cash and cash equivalents Profit before tax Depreciation and amortization CAPEX Others Repayment of debt Others FX Impact Investing CF -33 Financing CF -100 Dividend Repayment of lease liabilities Operating CF +143 Others Interest expenses Interest paid Income taxes paid +21 Working capital (JPY in 100 millions)
Page 19
FY26 Full Year Forecasts 03
Page 20
20 ©PHC Holdings Corporation 2026 FY26 Full Year Consolidated Forecasts(No revisions from May 2026 announcement) FY25 Results FY26 Forecasts YoY Variance YoY Variance (%) Revenue 3,644 3,597 -47 -1.3% Operating Profit 227 270 +43 +19.0% Profit Before Tax 64 220 +156 +244.3% Profit Attributable to Owners of Parent 5 154 +149 - Basic Earnings Per Share (JPY) 4 122 +118 - EUR / USD Against JPY 175 / 151 165 / 145 -10 / -6 - Annual Dividend (JPY) 42 42 0 - (JPY in 100 millions) EBITDA 498 532 +34 +6.8% Adjusted EBITDA 520 536 +16 +3.2%
Page 21
21 ©PHC Holdings Corporation 2026 FY25 Results* FY26 Forecasts YoY Variance YoY Variance (%) Revenue Diabetes Management 1,016 923 -93 -9.1% Healthcare Solutions 1,284 1,321 +37 +2.9% Diagnostics & Life Sciences 1,343 1,352 +9 +0.7% HQ & Others 1 1 -0 -27.5% Consolidated 3,644 3,597 -47 -1.3% Operating Profit (Operating profit margin: %) Diabetes Management 201 19.8% 240 26.0% +39 +19.5% Healthcare Solutions 62 4.9% 65 4.9% +3 +4.3% Diagnostics & Life Sciences 46 3.4% 49 3.6% +3 +6.5% HQ & Others -82 - -84 - -2 - Consolidated 227 6.2% 270 7.5% +43 +19.0% Adjusted EBITDA (Adjusted EBITDA margin: %) Diabetes Management 256 25.2% 284 30.8% +28 +11.0% Healthcare Solutions 172 13.4% 171 12.9% -1 -0.4% Diagnostics & Life Sciences 160 11.9% 157 11.6% -3 -2.1% HQ & Others -68 - -76 - -8 - Consolidated 520 14.3% 536 14.9% +16 +3.2% FY26 Full Year Segment Forecasts (JPY in 100 millions) *Starting in FY26, the B2B business in Indonesia, previously included in "HQ & Others“, was incorporated into “Diagnostics & Life Sciences”. Please refer to page 27 for details. Figures for FY25 are restated.
Page 22
Appendix 04
Page 23
23 ©PHC Holdings Corporation 2026 [Diagnostics & Life Sciences Segment] Life Sciences Revenue Breakdown FY25 Q1 FY26* Q1 YoY Variance YoY Variance (%) Biomedical 112 119 +7 +6.6% IVD 41 41 +0 +0.8% B2B Business in Indonesia 14 15 +1 +10.8% Life Sciences Total 166 175 +9 +5.6% *Reference figures based on the previous business classification (JPY in 100 millions)
Page 24
24 ©PHC Holdings Corporation 2026 FX Sensitivity (JPY in millions) Currencies Pair Revenue Operating Profit JPY / EUR +375 +50 JPY / USD +470 +25 PHC Group is exposed to the following impacts on its full year results depending on the respective change in exchange rates (depreciation of JPY 1 throughout the year). The Group is primarily affected by EUR and USD, besides JPY. The three currencies account for approx. 85% of revenue and approx. 95% of operating profit.
Page 25
25 ©PHC Holdings Corporation 2026 FX Gains and Losses Recognized in Financial Income and Expenses FX gains and losses resulting from the settlement and FX valuation of receivables and payables denominated in foreign currencies. • FX valuation losses included in financial expenses for FY26Q1 YTD: JPY 0.6 billion (FY25Q1 YTD: 4.4 billion) Due to weaker JPY against EUR at FY26Q1-end compared to FY25Q4-end, FX valuation losses were primarily incurred on the Company’s EUR-denominated borrowings from a subsidiary outside Japan. FX valuation gains or losses on these borrowings fluctuate with changes in the FX rate and these are unrealized. Since these are internal transactions, no external cash outflow occurs at settlement (excluding related cost). The corresponding FX translation impact on the EUR loan receivable held by the subsidiary outside Japan is included in other comprehensive income (OCI) which is part of the Group’s equity.
Page 26
26 ©PHC Holdings Corporation 2026 Diabetes Management, Healthcare IT Solutions • Even if the important assumptions used to determine impairment were to change within a reasonably foreseeable range, a significant impairment loss is not likely to be incurred. • Balance as of FY25-end: Diabetes Management JPY 139,095 million, Healthcare IT Solutions JPY 18,217 million Pathology • As a result of the impairment test, the recoverable amount exceeded the book value. However, if the before-tax discount rate were to rise by 0.5% or the growth rate were to decline by 0.9%, the recoverable amount would match the book value. - Assumptions: Discount rate (before-tax) 11.7%, growth rate 2.5% • Balance as of FY25-end: JPY 60,262 million Major Goodwill Items (Disclosed in Japan Securities Report)
Page 27
27 ©PHC Holdings Corporation 2026 Name Clarification and Reorganization of Business Units Effective FY26 The names of the BGM and LSIM Business Units were clarified as the Diabetes Management Business Unit and the Clinical Testing Business Unit, respectively. The Biomedical and IVD Business Units were integrated into a single BU called the Life Sciences Business Unit. The B2B business in Indonesia, previously included in Others, was transferred to the Life Sciences Business Unit. *PHCbi continues as a product brand. FY26 onward FY25 Others • Indonesia B2B Business • Head Office and Others • Head Office and Others BGM Business Unit LSIM Business Unit Healthcare IT Solutions Business Unit CRO Business Unit Pathology Business Unit IVD Business Unit Diagnostics & Life SciencesDiabetes Management Healthcare Solutions Biomedical Business Unit * Diabetes Management Business Unit Clinical Testing Business Unit Healthcare IT Solutions Business Unit CRO Business Unit Pathology Business Unit Life Sciences Business Unit
Page 28
28 ©PHC Holdings Corporation 2026 Glossary *These are not measures in accordance with IFRS Accounting Standards. EBITDA EBITDA = Operating profit + depreciation + impairment loss (excluding marketable securities) Adjusted EBITDA Adjusted EBITDA = EBITDA + one-time income and expense Excluding FX Impact Excluding FX Impact is calculated as follows; - Revenue : IFRS Revenue – FX impact on Revenue - Operating Profit : IFRS Operating Profit – FX impact on Operating Profit - Adjusted EBITDA: Adjusted EBITDA – FX impact on Adjusted EBITDA DM Diabetes Management HS Healthcare Solutions D&LS Diagnostics & Life Sciences BGM Blood Glucose Monitoring CGM Continuous Glucose Monitoring IVD In Vitro Diagnostics Business Finance*
Page 29
29 ©PHC Holdings Corporation 2026 Historical Financial Data The following data are available on our website. Consolidated Balance Sheet Profit & Loss including adjustment items Cash Flow Statement Segment Revenue, Operating Profit, Adjusted EBITDA including adjustment items Revenues in each of the Business Units and Revenue Matrix of Segments and Regions Quarterly Data From FY24 to FY26Q1 Include: https:// www.phchd.com /global/ ir/historical